A recent study [67] reported that vaginal bromocriptine treatment (5 mg for 6 months) did not change the prolactin mRNA expression and concentration of prolactin in endometrial tissues, but inhibited the proliferation of endometrial tissue in adenomyosis as well as the capability of adenomyotic tissue to migrate in part through the regulation of dysregulated micro RNAs and signalling pathways associated with the proliferation of endometrial stromal cells. The gene discussed is PRL; the disease is adenomyosis.